Mapping a Path to
Breakthrough Therapies

Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer

Discover the science
Snipe kartos chain

MDM2

KRT-232

p53

The MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients with Myelofibrosis (MF), Polycythemia Vera (PV), Acute Myeloid Leukemia (AML), and Merkel Cell Carcinoma (MCC)

KRT-232

A novel, potent, and selective oral MDM2 inhibitor

Active Clinical Studies

KRT-232

MDM2

Snipe krt232 mdm2 mobile